Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) - Episode 1

Trends in ESCC Incidence and Observations from Clinical Practice

,

Nabil Saba, MD, FACP and Harry Yoon, MD, briefly review the incidence of esophageal squamous cell carcinoma (ESCC), and describe how many patients present with unresectable locally advanced or metastatic disease in their clinical practice.

Now Viewing
EP. 1: Trends in ESCC Incidence and Observations from Clinical Practice
EP. 2: Approaches to Biomarker Testing for ESCC
EP. 3: The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
EP. 4: First-Line Options for Advanced/Metastatic Disease
EP. 5: Insights on ESCC First-Line Treatment Selection
EP. 6: RATIONALE-306 Data on Tislelizumab in ESCC
EP. 7: The Potential Impact of Tislelizumab on First-Line ESCC Treatment
EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
EP. 9: A Look Towards the Future of ESCC

Related Content:

Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)OncLive News Network®
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Overcoming Barriers to NSCLC Biomarker Testing
Challenges of NSCLC Biomarker Testing in Clinical Practice